Therapeutic efficacy of FASN inhibition in preclinical models of HCC.
Sign Up to like & getrecommendations! Published in 2022 at "Hepatology"
DOI: 10.1002/hep.32359
Abstract: BACKGROUND & AIMS Aberrant activation of fatty acid synthase (FASN) is a major metabolic event during the development of HCC. We evaluated the therapeutic efficacy of TVB3664, a novel FASN inhibitor, either alone or in… read more here.
Keywords: hcc treatment; tvb3664; efficacy fasn; therapeutic efficacy ... See more keywords
Cabozantinib for HCC Treatment, From Clinical Back to Experimental Models
Sign Up to like & getrecommendations! Published in 2021 at "Frontiers in Oncology"
DOI: 10.3389/fonc.2021.756672
Abstract: Hepatocellular carcinoma (HCC) is the fourth leading cause of cancer-related mortality worldwide. Patients with early-stage HCC can be treated successfully with surgical resection or liver transplantation. However, the usual late diagnosis of HCC precludes curative… read more here.
Keywords: treatment clinical; cabozantinib hcc; hcc; treatment ... See more keywords